Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines.
Annually, influenza virus infects millions of people worldwide. Vaccination programs against seasonal influenza infections require the production of hundreds of million doses within a very short period of time. The influenza vaccine is currently produced using a technology developed in the 1940s tha...
| Publicado en: | BioMed Research International Vol. 2015; pp. 1 - 12 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
3/1/2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109273511&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109273511 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 3/1/2015 vid: 2015 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 109273511 109273511 109273511 10.1155/2015/504831 109273511 ppf: 1 ppct: 11 formats: fmt: @attributes: type: P tig: atl: Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines. aug: au: Milián, Ernest Kamen, Amine A. affil: Department of Bioengineeringt, McGill University, Macdonald Engineering Building, 817 Sherbrooke Street W, Montreal, QC, Canada, H3A 0C3 sug: subj: Drug Compounding Methods Cell Culture Techniques Technology, Pharmaceutical Drug Design Methods Influenza Vaccine Classification Influenza, Seasonal Prevention and Control Orthomyxoviridae Analysis Specimen Handling Genetic Engineering Methods Biotechnology Methods United States Food and Drug Administration ab: Annually, influenza virus infects millions of people worldwide. Vaccination programs against seasonal influenza infections require the production of hundreds of million doses within a very short period of time. The influenza vaccine is currently produced using a technology developed in the 1940s that relies on replicating the virus in embryonated hens’ eggs. The monovalent viral preparation is inactivated and purified before being formulated in trivalent or tetravalent influenza vaccines. The production process has depended on a continuous supply of eggs. In the case of pandemic outbreaks, this mode of production might be problematic because of a possible drastic reduction in the egg supply and the low flexibility of the manufacturing process resulting in a lack of supply of the required vaccine doses in a timely fashion. Novel production systems using mammalian or insect cell cultures have emerged to overcome the limitations of the egg-based production system. These industrially well-established production systems have been primarily selected for a faster and more flexible response to pandemic threats. Here, we review the most important cell culture manufacturing processes that have been developed in recent years for mass production of influenza vaccines. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|